ENZ - Enzo Biochem, Inc.
2.95 0.00 (0.00%)
After hours: 5:17PM EST
| Previous Close | 3.2700 |
| Open | 3.1100 |
| Bid | 2.25 x 800 |
| Ask | 3.25 x 2200 |
| Day's Range | 2.9200 - 3.2500 |
| 52 Week Range | 2.9200 - 9.0600 |
| Volume | 275,463 |
| Avg. Volume | 159,538 |
| Market Cap | 139.218M |
| Beta (3Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.22 |
| Earnings Date | Jun 9, 2017 - Jun 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
- Associated Press•yesterday
Enzo Biochem: Fiscal 1Q Earnings Snapshot
The New York-based company said it had a loss of 13 cents per share. The life sciences and biotechnology company posted revenue of $21.3 million in the period. In the final minutes of trading on Monday, ...
- Business Wire•yesterday
Enzo Biochem Reports Fiscal 2019 First Quarter Results
Recent Reimbursement Cuts Emphasize Value of Enzo’s Strategy
- Business Wire•5 days ago
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2019 Results Tuesday, December 11, 2018 at 8:30 AM E.T.
Enzo Biochem, Inc. , an integrated diagnostic and therapeutics company, will hold a conference call to discuss fiscal 2019 first quarter results Tuesday, December 11, 2018, at 8:30 AM E.T.
- Business Wire•8 days ago
Enzo Biochem Reports Publication of Study on Therapeutic Candidate SK1-I Detailing Promising Results in a Model of Treatment-Resistant Breast Cancer
Enzo Biochem, Inc. (ENZ), an integrated diagnostics and therapeutics company, today reported the publication of a study in the Journal of Lipid Research by researchers at a collaborating institution that shows SK1-I, the company’s proprietary Sphingosine Kinase 1 inhibitor drug candidate, was effective in reversing resistance to the breast cancer drug tamoxifen in a tamoxifen-resistant human breast cancer cell line. As pointed out in the publication, endocrine therapy, such as tamoxifen, is a first line treatment for estrogen receptor-positive breast cancer patients.
- Simply Wall St.•27 days ago
What Kind Of Shareholder Owns Most Enzo Biochem Inc (NYSE:ENZ) Stock?
The big shareholder groups in Enzo Biochem Inc (NYSE:ENZ) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...
- GlobeNewswire•last month
Market Trends Toward New Normal in Polaris Industries, NIKE, Charles River Laboratories International, Actuant, Caesarstone, and Enzo Biochem — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Benzinga•2 months ago
The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) Endo International PLC (NASDAQ: ENDP ) Krystal Biotech ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ENZ earnings conference call or presentation 16-Oct-18 12:30pm GMT
Q4 2018 Enzo Biochem Inc Earnings Call
- Benzinga•2 months ago
The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 15) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
- ACCESSWIRE•2 months ago
Enzo Biochem, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Enzo Biochem, Inc. (NYSE: ENZ ) will be discussing their earnings results in their 2018 FourthQuarter Earnings to be held on October16, 2018 at 8:30 AM Eastern ...
- Associated Press•2 months ago
Enzo Biochem: Fiscal 4Q Earnings Snapshot
NEW YORK (AP) _ Enzo Biochem Inc. (ENZ) on Monday reported a fiscal fourth-quarter loss of $5.8 million, after reporting a profit in the same period a year earlier. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
- Business Wire•2 months ago
Enzo Biochem Reports Fourth Quarter and Fiscal 2018 Results
Molecular Assay Approvals from New York State Department of Health and Planned Acquisition of New Facility Highlight Progress Advancing Growth Strategy
- Business Wire•2 months ago
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Fiscal 2018 Results Tuesday, October 16, 2018 at 8:30 AM E.T.
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday October 30, 2018.
- Investopedia•2 months ago
Top 5 Biotech Stocks for 2018
Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Given Celgene's solid long-term track record, the lackluster year-to-date performance may represent a buying opportunity.
- Investopedia•3 months ago
Top 5 Biotech Stocks for 2018
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
- Business Wire•3 months ago
Enzo Biochem to Acquire New Facility for Manufacturing and Distribution to Advance Its Diagnostic and Therapeutic Growth Strategy
Enzo Biochem, Inc. (ENZ), an integrated diagnostic and therapeutics company, announced today that, as part of implementing its growth strategy, it has entered into an agreement to purchase a commercial facility with nearly 36,000 square feet in Farmingdale, NY. The building is adjacent to the Company’s current Long Island campus and enhances the infrastructure needed to produce and distribute Enzo’s expanding low cost, diagnostic platform products and related services. The Company’s platform development includes automation-compatible reagent systems and associated products for sample collection and processing through analysis.
- Business Wire•5 months ago
Enzo Biochem Reports Validation of Three High Quality, Low Cost Biomarkers for Detecting Cancers and Their Progression, Especially in Women’s Health Area
Enzo Biochem Inc. (ENZ) today announced the validation of three clinically relevant, cost-efficient biomarker detection tests for charting the progression of various cancers, especially in the field of women’s health. The validated tests complement Enzo’s POLYVIEW® immunohistochemistry (“IHC”) and in situ hybridization (“ISH”) detection platform, an enhanced diagnostic detection system used by pathologists in reading tissue biopsies and favorably cited by a leading peer review publication for showing no false positives.
- Investopedia•5 months ago
Top 5 Biotech Stocks for 2018
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
- ACCESSWIRE•5 months ago
Blog Exposure - Bruker Buys Dutch Milk Analysis Equipment Manufacturer Lactotronic to Expand its Presence in the Dairy Industry
LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want access to our free research report on Bruker Corp. (NASDAQ: BRKR), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BRKR as the Company's latest news hit the wire. On July 03, 2018, the Company announced that it has signed an agreement to acquire the entire business of Drachten, The Netherlands-based Lactotronic B.V. Lactotronic specializes in developing, manufacturing, and distributing milk analyzing equipment and instruments for the dairy industry. Active-Investors.com is currently working on the research report for Enzo Biochem, Inc. (NYSE: ENZ), which also belongs to the Healthcare sector as the Company Bruker.
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of ENZ earnings conference call or presentation 12-Jun-18 12:30pm GMT
Q3 2018 Enzo Biochem Inc Earnings Call
- Benzinga•6 months ago
Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 11) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
- Associated Press•6 months ago
Enzo Biochem: Fiscal 3Q Earnings Snapshot
The New York-based company said it had a loss of 6 cents per share. The life sciences and biotechnology company posted revenue of $25.6 million in the period. Enzo Biochem shares have decreased 18 percent ...
- Business Wire•6 months ago
Enzo Biochem Reports Third Quarter Results
Enzo Biochem Inc. , an integrated diagnostic company, today reported results for the third fiscal quarter and nine months ended April 30, 2018, in addition to noting significant progression of its strategic plan aimed at providing cost-effective, high performing and easily adaptable products and services to hospital and independent laboratories.
- Business Wire•6 months ago
Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2018 Results Tuesday, June 12, 2018 at 8:30 AM E.T.
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday June 26, 2018.
